Medindia
Medindia LOGIN REGISTER
Advertisement

Genomics Likely to Replace Traditional Drug Therapies in Treating CHF

Friday, April 18, 2008 General News
Advertisement
NEW YORK, April 17 The market for congestive heart failure(CHF) drug treatments was estimated at $18 billion in 2007, and is expected toreach $30 billion by 2017, according to a new report by Kalorama Information,Congestive Heart Failure: Major World Markets, Volume I: PharmaceuticalManagement. Growth is being driven by three factors: an increased incidence ofCHF, the application of innovative technologies in search of targetedtherapies which is creating opportunity for new entrants into this market, andphysicians prescribing multi-drug regimens in response to the failure oftraditional drugs to treat CHF.
Advertisement

CHF is a complex disorder for which prevention is more effective thantreatment, and as part of the larger cardiovascular markets, it is mostlytreated with drugs used to treat many other cardiovascular disorders. The lackof targeted treatments means drugs will continue to be applied liberally forprevention and sales will grow disproportionately to the CHF patientpopulation.
Advertisement

"The future of CHF drug treatments lies in newer technologies such asbiotechnology and genomics," notes Kenneth Krul, the report's analyst. "Theidentification of fetal genes associated with CHF, new treatments that addressthe endothelium and cell therapy to regenerate damaged heart muscle tissuepresent some promising areas."

The market for drugs to treat CHF will continue to be dominated by majorpharmaceutical companies which supply product lines with broad cardiovascularapplications. There are, however, many smaller companies focusing primarily onCHF and biotech, and their numbers are growing with the realization that thisdisease presents a major economic opportunity for which there is currently noadequate answer.

Kalorama Information's report Congestive Heart Failure: Major WorldMarkets, Volume I: Pharmaceutical Management focuses on the market potentialresulting from the application of current and advanced pharmaceutical andbiopharmaceutical technology to the development of CHF treatments in the U.S.,France, Germany, Italy, Spain, United Kingdom and Japan, providing forecaststhrough 2017. The report can be purchased directly from Kalorama Informationby visitinghttp://www.kaloramainformation.com/Congestive-Heart-Failure-1399514/.

About Kalorama Information

Kalorama Information supplies the latest in independent market research inthe life sciences, as well as a full range of custom research services.Kalorama routinely assists media with healthcare topics, and can provideexperts to speak about markets in the life sciences industry. For moreinformation, contact Andrea Hiller at 212-807-2673 [email protected], or visit http://www.kaloramaInformation.com.

SOURCE Kalorama Information
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close